From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

FREE Podcast: ShareProphets Radio Edition 1 with Tom Winnifrith

By Tom Winnifrith | Wednesday 24 July 2019


Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Excuse my croaky voice. In this inaugural edition of the ShareProphets Radio podcast sponsored by Riverfort Global Capital, this week, in order I discuss the pot bubble, interview Nigel Somerville on Neil Woodford, flag up my next 3 FRC PLC victims, interview outspoken broker Andrew Monk, discuss why CSR is a waste of cash and interview Steve O'Hara of Optibiotix (OPTI). Enjoy. If you like this and can't wait seven days for more of the same you should listen to my Bearcast every day.


This episode is sponsored by Riverfort Capital

This story is available to all readers
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:


Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

AAU

Gold up Ariana down

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

Time left: 09:02:43